News

The partnership targets membrane proteins, intracellular protein–protein interactions and complex receptor systems through a new drug discovery platform. It aims to target disease areas where conventional small-molecule drug

The partnership aims to investigate ways to implement quantum computing solutions throughout the healthcare value chain, with a focus on resource allocation, research and development, and patient outcomes

The contract covers a full technology transfer for the vaccine manufacturing process from Bavarian Nordic to SII, aiming to increase production capacity and future supply for endemic low-

Neupharma will gain exclusive rights for the development and commercialisation of the therapy, addressing a condition currently lacking approved targeted treatments. The company will fund and conduct a

As part of the agreement, Idorsia will receive an upfront payment and retain marketing authorisations in each country. Following local regulatory approval, the company will supply the finished

The approval marks the first authorised treatment for cerebral folate deficiency, a rare genetic neurological disorder affecting brain folate transport. It followed a systematic review of published literature,

This marks the first domestic anti-PD-1 monoclonal antibody in a subcutaneous formulation to reach the marketing application stage. JS001sc is independently developed by Junshi Biosciences as a subcutaneous

The collaboration will integrate NewcelX’s NCEL-101 with Eledon’s investigational anti-cluster of differentiation 40 ligand (anti-CD40L) monoclonal antibody, tegoprubart (AT-1501), to support durable, immune-protected islet replacement and develop a

Ecnoglutide is a cyclic adenosine monophosphate (cAMP)-biased glucagon-like peptide-1 (GLP-1) receptor agonist intended for chronic weight management in Chinese adults with obesity or who are overweight. It is